- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02034734
A Study to Investigate the Appearance and Disappearance of ASP3652 in Blood and Spinal Fluid in Healthy Male Subjects
A Phase I, Open-label Study to Investigate the Safety, Tolerability and Plasma and Cerebrospinal Fluid Pharmacokinetics and Pharmacodynamics of Multiple Doses of ASP3652 in Healthy Young Caucasian Male Subjects
Study Overview
Status
Intervention / Treatment
Detailed Description
Screening takes place between Day -22 to Day -2. Subjects are admitted to the clinical on Day -1 and remain until Day 12.
On Days 5 to 9, subjects receive twice-daily doses of ASP3652, and a single dose on the morning of Day 10. Subjects fast for 10h before the morning dose on Days 5 to 9 and they are served the first standard meal 1h after the morning dose.
A spinal tap is used to collect cerebrospinal fluid (CSF) on Day 1 and Day 10. A plasma sample for PK sample is obtained before first dosing on Day 5. To confirm steady-state concentrations of ASP3652 in plasma, blood samples are obtained before the morning dose on Days 7, 9 and 10, and before the evening dose on Days 5, 7 and 9. On Day 10, a PK profile of ASP3652 in plasma is obtained for up to 48h after the morning dose and for up to 24h in CSF.
Profiles of several enzyme substrates in plasma and seminal fluid (exploratory) are obtained on Day 1 and Day 10 up to 24h in CSF and up to 48h in plasma, before the morning and evening dose on Days 5, 7 and 9 in plasma.
Vital signs, 12-lead electrocardiograms (ECGs), safety laboratory assessments, adverse events (AEs) and concomitant medication are monitored throughout the investigational period until the ESV.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Harrow, United Kingdom, HA1 3UJ
- PAREXEL Early Phase Clinical Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is white and of Caucasian origin.
- Body Mass Index more than or equal to 18.5 and less than 30.0 kg/m2.
- Male subject must agree to practice an adequate contraceptive method with female sexual partners to prevent pregnancy.
Exclusion Criteria:
- Known or suspected hypersensitivity to ASP3652 or any components of the formulation used.
- History of excessive bleeding or bruising.
- Abnormalities of coagulation screen including platelet count, prothrombin time (PT) and activated partial thromboplastin time (aPTT).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1: ASP3652
Multiple doses of ASP3652
|
oral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics (PK) of ASP3652 in plasma measured by area under the plasma concentration-time curve in the dosing interval (AUCtau)
Time Frame: Days 5, 7 and 9, and Days 10 - 12
|
Days 5, 7 and 9, and Days 10 - 12
|
PK of ASP3652 in plasma measured by maximum observed plasma concentration (Cmax)
Time Frame: Days 5, 7 and 9, and Days 10 - 12
|
Days 5, 7 and 9, and Days 10 - 12
|
PK parameter of ASP3652 in cerebrospinal fluid (CSF) measured by area under the plasma concentration-time curve in the dosing interval (AUCtau)
Time Frame: Days 10 -11
|
Days 10 -11
|
PK parameter of ASP3652 in cerebrospinal fluid (CSF) measured by maximum observed plasma concentration (Cmax)
Time Frame: Days 10 -11
|
Days 10 -11
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Additional PK of multiple doses of ASP3652 in plasma and cerebrospinal fluid (CSF)
Time Frame: Plasma: Days 5, 7 and 9, and Days 10 - 12 / CSF: Days 10 -11
|
plasma concentration immediately before the next dose (Ctrough), time to attain Cmax (tmax), apparent terminal elimination half-life (t½), volume of terminal phase distribution at steady state (Vz/F), apparent clearance after oral administration at steady state (CL/F) and peak trough ratio (PTR)
|
Plasma: Days 5, 7 and 9, and Days 10 - 12 / CSF: Days 10 -11
|
Pharmacodynamics (PD) of multiple doses of ASP3652 in plasma and CSF
Time Frame: Plasma: Days 1-3 and Days 5-12 / CSF: Days 1-2 and Days 10-11
|
response immediately prior to dosing (Rtrough), time of the maximum response (tmaxR), maximum response (Rmax), area under the response-time curve from 0 to 12h (AURC0-12h), percentage change in maximum response (Rmax%), percentage change in AURC from 0 to 12h (AUR0-12h%)
|
Plasma: Days 1-3 and Days 5-12 / CSF: Days 1-2 and Days 10-11
|
Safety and tolerability of multiple doses of ASP3652
Time Frame: Screening (Day -22 to Day -2) to End-of-Study Visit (7 to 14 days after (early) discharge)
|
Screening (Day -22 to Day -2) to End-of-Study Visit (7 to 14 days after (early) discharge)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 3652-CL-0048
- 2011-004226-97 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
NeuShen TherapeuticsNot yet recruiting
-
GEN İlaç ve Sağlık Ürünleri A.Ş.Sulfateq B.V.Recruiting
-
Bio-innova Co., LtdNot yet recruiting
-
Bio-innova Co., LtdNot yet recruiting
Clinical Trials on ASP3652
-
Astellas Pharma Europe B.V.CompletedHealthy Subjects | Pharmacokinetics of ASP3652United Kingdom
-
Astellas Pharma Europe B.V.CompletedHealthy Subjects | Pharmacokinetics | Pharmacodynamics | Effect of RaceUnited Kingdom
-
Astellas Pharma IncCompletedChronic Pelvic Pain Syndrome | Chronic Abacterial ProstatitisCzech Republic, Germany, Latvia, Lithuania, Poland, Spain
-
Astellas Pharma Europe B.V.CompletedPain | Urologic Diseases | Cystitis, Interstitial | Urinary Bladder DiseaseBelgium, Czechia, Denmark, Germany, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Russian Federation, Spain
-
Astellas Pharma Europe B.V.CompletedHealthy Subjects | Pharmacokinetics of ASP3652 | Pharmacodynamics of ASP3652Netherlands
-
Astellas Pharma Europe B.V.CompletedHealthy Subjects | Pharmacokinetics | Pharmacodynamics | SafetyNetherlands
-
Astellas Pharma Europe B.V.CompletedHealthy Subjects | Drug-Drug Interaction (DDI)United Kingdom